S100B, a Ca2+ binding protein mainly produced and released by astrocytes in the CNS, has been described as a potential biomarker of MS disease pathology and also as a potential therapeutic target (Barateiro et al. 2016). This evidence concerns the gene S100B and myeloid sarcoma.